Copy
SectorReport - Healthcare Powered by SmarterAnalyst.com
View this email in your browser

September 28, 2017 - Healthcare
This Healthcare report is brought to you by SmarterAnalyst

Weekly Update
Last Week's Performance
  • Long pick HOLX had a return of -0.614%.
  • Long pick CORI had a return of 1.214%.
  • Long pick NBRV had a return of -0.119%.
  • Short pick NVRO had a return of -3.845%.
Visit the archive to view trade history.
Sector Return
-0.94%
Portfolio Quick View
BeiGene, Ltd. (BGNE)
The long pick Vedanta Ltd along with its subsidiaries is a diversified natural resource company engaged in exploring extracting and processing minerals and oil and gas. It explores metals & minerals, Oil & gas and also involved in power generation activities.
Avadel Pharmaceuticals (AVDL)
The long pick Flamel Technologies is a biopharmaceutical company mainly engaged in the development of two unique polymer-based drug delivery technologies for the improvement of medical applications.
Apollo Endosurgery (APEN)
The long pick Lpath, Inc. is a biotechnology company engaged in the discovery and development of lipidomic-based therapeutic antibodies to treat a wide range of human diseases. The Company's product candidates include iSONEP, ASONEP, Lpathomab, and ImmuneY2 Technology.
Endologix (ELGX)
The short pick Endologix Inc develops, manufactures, markets & sells medical devices for the treatment of aortic disorders. Its main product is a stent graft & delivery system for the treatment of abdominal aortic aneurysms through minimally-invasive EVAR or EVAS.
Analysis & Research

Using TipRanks' algorithms we are able to search the web for all relevant information about each pick. Below we provide blogger, analyst, news, and insider coverage for any activity, transactions or reccomendations.

Long: BeiGene, Ltd. (BGNE)

Recent Analysts Ratings
  • Analyst Gabrielle of Maxim Group reccomends buying BGNE with a 1 year price target of $77.00
  • Analyst Gabrielle of Maxim Group reccomends buying BGNE with a 1 year price target of $77.00
  • Analyst Gabrielle of Maxim Group reccomends buying BGNE with a 1 year price target of $77.00
News Worth Mentioning
  • Yahoo Finance: BeiGene Announces Presentation at the 20th Annual Meeting of the Chinese Society of Clinical Oncology (open)
  • Yahoo Finance: BeiGene Presents Preliminary Phase 1 Data for BGB-A317 in Multiple Solid Tumors at the ESMO 2017 Congress (open)
  • Yahoo Finance: BeiGene Presents Preliminary Phase 1/2 Clinical Data on PARP Inhibitor BGB-290 in Patients with Advanced Solid Tumors at the European Society for Medical Oncology 2017 Congress (open)
  • Yahoo Finance: BeiGene Presents Preliminary Phase 1/2 Clinical Data on PARP Inhibitor BGB-290 in Patients with Advanced Solid Tumors at the European Society for Medical Oncology 2017 Congress (open)
  • Yahoo Finance: BeiGene Announces Closing of Global Strategic Oncology Collaboration with Celgene Corporation (open)

Long: Avadel Pharmaceuticals (AVDL)

News Worth Mentioning
  • Yahoo Finance: Avadel Pharmaceuticals Enters into Exclusive License Agreement for Noctiva™ (open)
Insider Transactions
  • Insider Peter Thornton bought shares valued at $50209.70 on 9/25/2017
  • Insider Sandra Hatten bought shares valued at $55503.00 on 9/15/2017
  • Insider THOMPSON PHILLANDAS T. bought shares valued at $46800.00 on 9/14/2017
  • Insider ANDERSON MICHAEL S bought shares valued at $39160.00 on 9/14/2017
  • Insider DIVIS GREG J bought shares valued at $98686.00 on 9/14/2017

Long: Apollo Endosurgery (APEN)

Recent Analysts Ratings
  • Analyst Suraj of Northland Securities reccomends buying APEN with a 1 year price target of $12.00
Insider Transactions
  • Insider Rick Anderson bought shares valued at $685390.00 on 9/25/2017
  • Insider Ptv Sciences LP bought shares valued at $685390.00 on 9/25/2017
  • Insider Matthew S. Crawford bought shares valued at $685390.00 on 9/25/2017
  • Insider McWilliams Dennis L. bought shares valued at $50612.32 on 9/19/2017

Short: Endologix (ELGX)

Recent Analysts Ratings
  • Analyst Jason of Canaccord Genuity reccomends holding ELGX with a 1 year price target of $5.00
  • Analyst Joanne of BMO Capital reccomends holding ELGX with a 1 year price target of $5.00
  • Analyst Nicholas of RBC Capital reccomends holding ELGX with a 1 year price target of $5.00
News Worth Mentioning
  • Yahoo Finance: Endologix Announces CE Mark Approval for the Nellix® EndoVascular Aneurysm Sealing System with the Refined Indications for Use (open)
General Information
General Information

Data provider: TipRanks.com
Investment horizon: Weekly
Universe: US Healthcare

The audited historical performance of this strategy and information regarding allocation and strategy can be found on the official Smarter Analyst page for SectorReport.
License Information
Member: <<First Name>> <<Last Name>>
Contract: <<Type>>
License #: <<Member ID>> 

*No portion of the above message and file may be republished, re-transmitted or forwarded without express written consent from SmarterAnalyst.com 
Questions? Contact us at premium@smarteranalyst.com
Disclaimer: The advice provided on this newsletter is SmarterAnalyst's general advice only. It has been prepared without taking into account your objectives, financial situation or needs. Before acting on this advice you should consider the appropriateness of the advice, having regard to your own objectives, financial situation and needs. If any products are detailed on this website, you should obtain a Product Disclosure Statement relating to the products and consider its contents before making any decisions. Where quoted, past performance is not indicative of future performance. SmarterAnalyst disclaims all and any guarantees, undertakings and warranties, expressed or implied, and shall not be liable for any loss or damage whatsoever (including human or computer error, negligent or otherwise, or incidental or consequential loss or damage) arising out of or in connection with any use or reliance on the information or advice on this newsletter. The user must accept sole responsibility associated with the use of the material on this newsletter, irrespective of the purpose for which such use or results are applied. The information on this newsletter is no substitute for financial advice.

Important: The links below are in compliance with international spam law; however, removing yourself from the newsletter's mailing list does not cancel the service! For any inquiries regarding upgrades/cancellations or billing please contact us directly at premium@smarteranalyst.com
Copyright © 2017 SmarterAnalyst, All rights reserved.


Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list